비스포스포네이트 제제와 골다공증 치료
Bisphosphonates and Osteoporosis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
비스포스포네이트 제제는 파골세포의 활성을 방해하여 골흡수를 저해하는 약제이다. 비스포스포네이트 제제는 폐경 여성에서 척추 골절 및 비척추 골절 감소시키는 목적으로 개발되어 왔고, 발매되고 있다. 비스포스포네이트 제제의 아주 드물지만 심각한 부작용은 턱부위의 골괴사가 있는데 이것은 대부분의 경우 종양환자에서 고용량의 비스포스포네이트제제를 사용했을 때 생길 수 있다. 이를 예방하기 위해서는 구강 위생과 적절한 치과 치료가 필요하다. 최근까지 비스포스포네이트 제제는 1) 알렌드로네이트, 2) 리제드로네이트, 3) 이반드로네이트 그리고 4) 졸레드로네이트 제제들이 미국 식품의약청으로부터 승인되어 사용되고 있다. 경구제제는 알렌드로네이트, 리제드로네이트와 이반드로네이트 제제가 있고 정맥주사제로는 이반드로네이트와 졸레드로네이트 제제가 사용되고 있다.
Abstract
The bisphosphonate class of drugs act to inhibit bone resorption by interfering with the activity of osteoclasts. Bisphosphonate was developed and marketed as an intervention to reduce vertebral and nonvertebral fractures in postmenopausal women. Bisphosphonate associated osteonecrosis of jaw(ONJ) is associated with high-dose bisphosphonate therapy primarily in the oncology patient population. Prevention and treatment strategies are currently based on expert opinion and focus on maintaining good oral hygiene and conservative surgical intervention. Currently, four bisphosphonates, 1) alendronate, 2) risedronate, 3) ibandronate, and 4) zoledronic acid, are approved in the United States. Alendronate, risedronate and ibandronate are oral agents, and ibandronate and zoledronic acid are intravenous drugs.
참고문헌 (11)
- Black DM, "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures", Lancet, 348, pp.1535~1541 (1996), Fracture Intervention Trial Research Group
- Cummings SR, "Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial", JAMA, 280, pp.2077~2082 (1998)
- Rizzoli R, "Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis", J Bone Miner Res, 17, pp.1988~1996 (2002), Alendronate Once-Weekly Study Group
- Bone HG, "Ten years' experience with alendronate for osteoporosis in postmenopausal women", N Engl J Med, 350, pp.1189~1199 (2004), Alendronate Phase III Osteoporosis Treatment Study Group
- Black DM, "Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial", JAMA, 296, pp.2927~2938 (2006), FLEX Research Group
- Harris ST, "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial", JAMA, 282, pp.1344~1352 (1999), Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
- Reginster J, "Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis", Osteoporos Int, 11, pp.83~91 (2000), Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
- McClung MR, "Effect of risedronate on the risk of hip fracture in elderly women", N Engl J Med, 344, pp.333~340 (2001), Hip Intervention Program Study Group
- Brown JP, "The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis", Calcif Tissue Int, 71, pp.103~111 (2002)
- Delmas PD, "Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study", Osteoporos Int, 10, pp.792~798 (2004)
- Black DM, "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. HORIZON Pivotal Fracture Trial", NEJM, 356, pp.1809~1822 (2007)